Skip to main content

Amifampridine Dosage

Medically reviewed by Drugs.com. Last updated on Jan 22, 2021.

Applies to the following strengths: 10 mg

Usual Adult Dose for Lambert-Eaton Myasthenic Syndrome

-Initial dose: 15 mg to 30 mg orally once a day in divided doses (3 to 4 times daily)
-Maximum single dose: 20 mg
-Maximum daily dose: 80 mg/day

Comments:
-Dose may be increased by 5 mg daily every 3 or 4 days.
-If a dose is missed, patients should not take double or extra doses.

Use: For the treatment of Lambert-Eaton myasthenic syndrome (LEMS)

Usual Pediatric Dose for Lambert-Eaton Myasthenic Syndrome

6 years to less than 17 years weighing less than 45 kg:
-Initial dose: 7.5 mg to 15 mg orally once a day in divided doses (2 to 3 times daily)
-Maximum single dose: 15 mg
-Maximum daily dose: 50 mg

Comments:
-Dose may be increased daily in 2.5 mg to 5 mg increments, divided in up to 5 doses daily.
-Dosage should be increased based on clinical response and tolerability.
-A suspension can be prepared when patients require a dosage in less than 5 mg increments.

6 years to less than 17 years weighing 45 kg or more:
-Initial dose: 15 mg to 30 mg daily in divided doses (2 to 3 times daily)
-Maximum single dose: 30 m
-Maximum daily dose: 100 mg

Comments:
-Dose may be increased daily in 5 mg to 10 mg increments, divided in up to 5 doses daily.
-Dosage should be increased based on clinical response and tolerability.

Use: For the treatment of Lambert-Eaton myasthenic syndrome (LEMS)

Renal Dose Adjustments

Adults:
Mild (CrCl 60 to less than 90 mL/min), moderate (CrCl 30 to less than 60 mL/min), or severe (CrCl 15 to less than 30 mL/min) renal impairment: The recommended starting dose is 15 mg orally once a day in 3 divided doses
End-stage (CrCl less than 15 mL/min) renal disease: Data not available

Pediatric patients weighing less than 45 kg:
Renal impairment: 7.5 mg orally once a day in divided doses
End-stage (CrCl less than 15 mL/min) renal disease: Data not available

Pediatric patients weighing 45 kg or more:
Renal impairment (creatinine clearance 15 to 90 mL/min): 15 mg orally once a day in divided doses
End-stage (CrCl less than 15 mL/min) renal disease: Data not available

Liver Dose Adjustments

Adults patients with any degree of hepatic impairment: 15 mg orally once a day in 3 divided doses

Pediatric patients weighing less than 45 kg with any degree of hepatic impairment: 7.5 mg orally once a day in divided doses

Pediatric patients weighing 45 kg or more with any degree of hepatic impairment: 15 mg orally once a day in divided doses

Dose Adjustments

Known N-acetyltransferase 2 (NAT2) Poor Metabolizers:
Adults:
-Initial dose is 15 mg orally once a day in 3 divided doses

Pediatrics:
-Weighing less than 45 kg: 7.5 mg orally once a day in divided doses
-Weighing 45 kg or more: 15 mg orally once a day in divided doses

Precautions

CONTRAINDICATIONS:
-Hypersensitivity to the active component or any of the ingredients
-History of seizures

Safety and efficacy in pediatric patients below the age of 6 years have not been established.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-This drug can be taken with or without food.
-The tablets may be divided in half at the score, if needed.
-Do not take a double dose to make up for a missed dose.
-Refer patients and/or caregivers to the Instructions for Use if they require a dosage in less than 5 mg increments, have difficulty swallowing tablets, or require feeding tubes.
-The prepared 1 mg/mL suspension should be prepared daily and refrigerated between doses.


Storage requirements:
-Store tablets at 20C to 25C with excursions permitted from 15C to 30C (59F to 86F).
-The suspension can be stored under refrigeration for up to 24 hours, discard any unused portion after 24 hours.

Patient advice:
-Read the patient information leaflet before taking this drug.
-Seek medical help immediately if you experience hypersensitivity or seizures.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.